Form 4: Relay Therapeutics Director, Mark Murcko, Reports Stock Option Grant

Mark Murcko, a director at Relay Therapeutics, reported the acquisition of stock options for 102,225 shares on June 3, 2024.

Summary

• Mark Murcko, a director of Relay Therapeutics, Inc. [RLAY], filed a Form 4 on June 5, 2024.
• The form reports a transaction that occurred on June 3, 2024, where Murcko acquired stock options for 102,225 shares of Relay Therapeutics common stock at an exercise price of $6.79.
• These options vest in full on the earlier of the first anniversary of the grant date (June 3, 2025) or the date of the next annual meeting of stockholders following the grant date.
• Following the reported transaction, Murcko directly owns 102,225 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options is a standard practice and aligns the director's interests with the company's success. There are no immediate negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The vesting of the options is contingent upon continued service or the occurrence of the next annual meeting, aligning the director's interests with the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders. This is a standard practice for companies like Relay Therapeutics to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options as part of their compensation strategy.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to incentivizing its leadership.

Key Dates